Nadia Mensali and Marit R. Myhre published a new study entitled: "Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy". A copy of the study published in Cancer Immunology, Immunotherapy can be found here.
We were at the last PIVAC (Progress in Vaccination Against Cancer) 2019 !
Else Marit and Hedvig presented our most recent developments !
Make sure to check their abstracts !
Yesterday Lizet Baken successfully defended her Bachelor Thesis at the Avans University of Applied Sciences.
Part of this thesis was performed in our lab where she has been working on an anti-Ig-lambda CAR.
Congratulations Lizet, we are all very proud of you!
Our collaborators published a new paper on TIGIT and PD-1 as markers of reduced effector function of T-cells in B-cell lymphoma.
Make sure to have a look here !
Gunnar Kvalheim, Hakan Köksal and Pierre Dillard will be at the next AACR meeting (29th of March to 3rd of April, Atalanta) to talk about new developments in CAR.
Hakan will present a novel combination method for IGKCAR that prevents B-cell aplasia.
Pierre will present the pre-clinical validation of CD37CAR, an alternative to CD19CAR.
Make sure to have a look!
Pierre Dillard will present our rescent work on the pre-clinical validation of CD37 CAR T-cells in Barcelona (11 - 13 March 2019).
Make sure to take a look at the abstract and at the conference website !
We published a new paper on redirected NK cells, transduced with TCR.
Make sure to take a look at the paper here !
New publication from Nadia Mensali in OncoImmunology.
This article decribe the loading of MCHI and II molecules by using CD74 constructs.
Make sure to check it out here!
We published a new review on the treatment of osteosarcoma by CAR therapy.
Make sure to have a looke here !
We published a new protocol on the assessment of CAR activity by spheroids. Have a look at our paper here and on the OCCi website news.
Emmanuelle Benard who did her PhD in Biophysics and Immunology in Marseille, just joined us !
She will be in charge of the development of new CAR T-cells.
We had our first JOVE shooting on a new metod to generate spheroid for CAR T-cells screening.
Make sure to give it a look (once it is out) !
PIVAC 2018 was held in Oslo, co-organized by the department of Cell Therpay. The conference permitted to share new advance in the field of vaccination and future prospects for immunotherapy.
Pierre Dillard will attend the 2018 meeting of the American Association for Cncer Research (AACR). He will present our recent work on universal killer, make sure to have a look !
Human c-SRC kinase (CSK) overexpression makes T cells dummy
Patient safety upon immunotherapy treatment is a challenge that still need to be adressed.
In this publication we report how by affecting c-SRC kinase we can make T-cells "dummy": effector cells are still able to recognize and bind to the target but unable to carry on with their activation. This mechanism could potentially open the way for a safe-lock system permitting to reduce off-target toxicity.
Image from: Ellen Tenstad/Science Shaped
Nadia Mensali was awarded with the presentation prize for her talk on the Universal Killer! See below to learn more
Nadia Mensali and Pierre Dillard will attend the 2017 meeting of the Society for ImmunoTherapy of Cancer (SITC). They will present our recent work on universal killer and CD4 Adoptive cell therapy, make sure to have a look !
Our team published a new paper about using TCR in CAR design, make sure to have a look here !
Marit Renee Myhre has been selected to give a talk at the 17th International Conference on Progress in Vaccination Against Cancer (PIVAC 2017) in Loutraki, Corinth, Greece
She will present our latest work on our new CD4-based therapy, make sure to have a look at the abstract if you want to learn more !
Our team has published a new paper in Translational Cancer Research:
New publication in our team: therapeutic T-cell receptors in healthy donor blood, is safety predictable? by Hakan Köksal and Sébastien Wälchli.
They are commenting a paper published in 2017 in Blood by Jahn et al. that presents a novel TCR-based therapy trageting intracellular transcription factor. Make sure to have a look at both papers!
